Elevated post-transfusion serum transaminase values associated with a highly significant trend for increasing prevalence of anti-Vesivirus antibody in Korean patients.
A highly significant increase in anti-Vesivirus (family Caliciviridae) antibody prevalence, along the axis from healthy blood donors; donors with elevated transaminase; patients with clinical hepatitis; and patients with post-transfusion/dialysis hepatitis, has been reported in human sera from the USA and Europe. Asian samples have now been tested retrospectively using serology and enzyme immunoassay (EIA) with a Vesivirus partial-capsid antigen expressed as a fusion protein. Anti-vesiviral antibodies were measured by optical densities (OD(650)) and compared in patients separated by age, gender and Groups A-F as follows: Control Group A, an Experimental Group B, which was divided further into Group C, patients with elevated enzymes (alanine transaminase (ALT), aspartate transaminase (AST), and γ-glutamyl transpeptidase (γ-GT); Group D, patients receiving transfused blood; Group E, patients with high enzyme levels after transfusion; and Group F, hepatitis B and C positive patients. Using multivariate logistic regression analyses, a significantly greater proportion of patients receiving transfusion(s), were positive for anti-Vesivirus antibody compared with non-transfused patients (P = 0.008; OR: 3.86, 95% CI: 1.43-10.43). Also, anti-Vesivirus antibody was significantly associated with elevated biochemical liver function tests: ALT ≥ 20 IU or AST ≥ 120 IU (P = 0.017; OR: 4.23, 95% CI: 1.30-13.80). In the blood transfusion group, anti-Vesivirus antibody was significantly correlated with high enzyme levels (ALT, P = 0.018; AST, P = 0.010; γ-GT, P = 0.020). These data provide serologic evidence of vesiviral transfusion-transmission-associated disease, which could include infection of any organ system where cytopathology resulted in high levels of either ALT or AST.
Department of Environmental Health and Institute of Health and Environment, School of Public Health, Seoul National University, Seoul, Korea.
Heetae
H
Lee
You-Hee
YH
Cho
Jeong Su
JS
Park
Eui-Chong
EC
Kim
Alvin W
AW
Smith
GwangPyo
G
Ko
D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood*; D000956:Antigens, Viral / Q000276:immunology; D001219:Aspartate Aminotransferases / Q000097:blood*; D001782:Blood Donors; D017250:Caliciviridae Infections / Q000453:epidemiology* / Q000276:immunology / Q000821:virology; D016022:Case-Control Studies; D016001:Confidence Intervals; D005260:Female; D016174:Hepacivirus / Q000276:immunology / Q000302:isolation & purification; D006509:Hepatitis B / Q000097:blood / Q000276:immunology / Q000635:transmission*; D006515:Hepatitis B virus / Q000276:immunology / Q000302:isolation & purification; D006526:Hepatitis C / Q000097:blood / Q000276:immunology / Q000635:transmission; D006801:Humans; D007124:Immunoenzyme Techniques; D008099:Liver / Q000201:enzymology / Q000473:pathology / Q000821:virology; D008111:Liver Function Tests / Q000379:methods; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D015995:Prevalence; D056910:Republic of Korea / Q000453:epidemiology; D065227:Transfusion Reaction; D029342:Vesivirus / Q000276:immunology* / Q000302:isolation & purification; D005723:gamma-Glutamyltransferase / Q000097:blood
D000914:Antibodies, Viral; D000956:Antigens, Viral; D005723:gamma-Glutamyltransferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase